| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 13 | 2024 | 1683 | 1.850 |
Why?
|
| Proto-Oncogene Proteins B-raf | 8 | 2025 | 222 | 1.780 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 19 | 1.440 |
Why?
|
| Melanoma | 6 | 2016 | 954 | 1.220 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2025 | 58 | 1.080 |
Why?
|
| Repressor Proteins | 5 | 2025 | 815 | 1.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 153 | 0.850 |
Why?
|
| Brain Abscess | 1 | 2024 | 54 | 0.850 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2024 | 169 | 0.830 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 249 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 332 | 0.800 |
Why?
|
| Neutropenia | 1 | 2024 | 205 | 0.780 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 93 | 0.770 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 47 | 0.750 |
Why?
|
| Matrix Metalloproteinase 14 | 4 | 2010 | 7 | 0.750 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 14 | 0.750 |
Why?
|
| Mutation | 15 | 2023 | 6250 | 0.670 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 42 | 0.660 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 11 | 0.640 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 97 | 0.630 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 293 | 0.630 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 131 | 0.620 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 175 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2025 | 234 | 0.600 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 897 | 0.590 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 42 | 0.580 |
Why?
|
| Neoplasms | 5 | 2022 | 2949 | 0.580 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 463 | 0.570 |
Why?
|
| Extracellular Matrix | 2 | 2009 | 238 | 0.530 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1541 | 0.510 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2021 | 215 | 0.510 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 571 | 0.490 |
Why?
|
| Medical Oncology | 2 | 2014 | 243 | 0.480 |
Why?
|
| ErbB Receptors | 2 | 2016 | 295 | 0.470 |
Why?
|
| cdc42 GTP-Binding Protein | 3 | 2010 | 33 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 87 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 402 | 0.450 |
Why?
|
| Genetic Techniques | 1 | 2014 | 104 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 947 | 0.420 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 454 | 0.420 |
Why?
|
| Humans | 51 | 2025 | 132373 | 0.410 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2025 | 38 | 0.410 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 143 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 663 | 0.370 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 1723 | 0.350 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 294 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 246 | 0.350 |
Why?
|
| Carcinoma | 1 | 2013 | 300 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 615 | 0.330 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 825 | 0.330 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 183 | 0.320 |
Why?
|
| Genetic Testing | 2 | 2019 | 1098 | 0.300 |
Why?
|
| Child | 16 | 2025 | 25835 | 0.290 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2025 | 241 | 0.290 |
Why?
|
| Genomics | 2 | 2021 | 1652 | 0.270 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 1409 | 0.270 |
Why?
|
| Transcriptome | 1 | 2013 | 1125 | 0.250 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 173 | 0.250 |
Why?
|
| Signal Transduction | 4 | 2015 | 4725 | 0.240 |
Why?
|
| Translocation, Genetic | 2 | 2025 | 359 | 0.230 |
Why?
|
| Quality Control | 2 | 2016 | 123 | 0.230 |
Why?
|
| Adolescent | 12 | 2025 | 20560 | 0.220 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2024 | 20 | 0.220 |
Why?
|
| Collagen | 4 | 2010 | 309 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 2064 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 356 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 180 | 0.200 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 146 | 0.200 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 2145 | 0.200 |
Why?
|
| Lipids | 1 | 2006 | 563 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 4 | 2022 | 1807 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 39 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 774 | 0.190 |
Why?
|
| Endonucleases | 2 | 2013 | 50 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 141 | 0.190 |
Why?
|
| Fibroma | 1 | 2022 | 31 | 0.190 |
Why?
|
| Female | 20 | 2025 | 70809 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 281 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 1018 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 76 | 0.180 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 46 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 148 | 0.180 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 1396 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 133 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 126 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 99 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 549 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 495 | 0.170 |
Why?
|
| Infant | 5 | 2025 | 13198 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 129 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2022 | 2494 | 0.170 |
Why?
|
| Cell Movement | 3 | 2009 | 891 | 0.170 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 147 | 0.170 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 81 | 0.170 |
Why?
|
| Sarcoma | 1 | 2022 | 208 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 74 | 0.160 |
Why?
|
| Cyclin B | 1 | 2019 | 23 | 0.160 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 21 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 148 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 20 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.160 |
Why?
|
| Male | 17 | 2025 | 65072 | 0.160 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 17 | 0.160 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 11 | 0.160 |
Why?
|
| Ependymoma | 1 | 2021 | 176 | 0.160 |
Why?
|
| Azacitidine | 1 | 2019 | 53 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 675 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1303 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 54 | 0.150 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 6 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 74 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2021 | 330 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 42 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 305 | 0.150 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 39 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 38 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 130 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 419 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2018 | 50 | 0.140 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 144 | 0.140 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 328 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 195 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 373 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 566 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 241 | 0.130 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 1997 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 775 | 0.130 |
Why?
|
| Thrombocytosis | 1 | 2017 | 34 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 816 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1035 | 0.130 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 4 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 102 | 0.130 |
Why?
|
| Prognosis | 6 | 2019 | 5010 | 0.120 |
Why?
|
| Heterozygote | 1 | 2018 | 717 | 0.120 |
Why?
|
| Survivors | 1 | 2018 | 359 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 33 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2010 | 530 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 41 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 57 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2016 | 77 | 0.120 |
Why?
|
| Calreticulin | 1 | 2015 | 23 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 728 | 0.120 |
Why?
|
| Ovary | 1 | 2018 | 371 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 23 | 0.120 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 16 | 0.120 |
Why?
|
| Apoptosis | 1 | 2022 | 1904 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 44 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 112 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2019 | 571 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 91 | 0.110 |
Why?
|
| Lipoma | 1 | 2013 | 26 | 0.100 |
Why?
|
| DNA Primers | 1 | 2014 | 637 | 0.100 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 21 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 637 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 151 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 991 | 0.100 |
Why?
|
| Models, Biological | 2 | 2009 | 1458 | 0.100 |
Why?
|
| Young Adult | 5 | 2025 | 9949 | 0.100 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2012 | 12 | 0.100 |
Why?
|
| Middle Aged | 8 | 2025 | 28895 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 85 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2025 | 14862 | 0.090 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2012 | 21 | 0.090 |
Why?
|
| Adult | 8 | 2025 | 31624 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1285 | 0.090 |
Why?
|
| Aged | 7 | 2016 | 21386 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3698 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 105 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1881 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 544 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 3024 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 122 | 0.090 |
Why?
|
| Exons | 1 | 2013 | 803 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7112 | 0.080 |
Why?
|
| Base Sequence | 1 | 2014 | 2904 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2014 | 938 | 0.080 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2009 | 38 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 493 | 0.080 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2009 | 110 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2009 | 106 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 215 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1458 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 691 | 0.070 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 4 | 0.070 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 10 | 0.070 |
Why?
|
| Sphingosine | 1 | 2006 | 17 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 390 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2006 | 33 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 368 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 63 | 0.060 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 68 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2025 | 6 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1047 | 0.060 |
Why?
|
| Receptors, Cytokine | 1 | 2025 | 67 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1829 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1297 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 364 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1964 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 82 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 98 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 1042 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 62 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 443 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 956 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 25 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 106 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 151 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 222 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 831 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1126 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2010 | 3062 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 284 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 591 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 76 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 421 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 3 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 1451 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 35 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 307 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 180 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 204 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2017 | 48 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 6457 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 21 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 657 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 72 | 0.030 |
Why?
|
| Polyps | 1 | 2016 | 43 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2015 | 21 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 5153 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 461 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 59 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1723 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
| Endometrium | 1 | 2016 | 274 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 408 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 879 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1348 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 303 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 246 | 0.020 |
Why?
|
| Uterus | 1 | 2016 | 547 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4695 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 295 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1009 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 18572 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2009 | 20 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2009 | 15 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 36 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2009 | 37 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4545 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 62 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 569 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 2706 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 72 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 35 | 0.020 |
Why?
|
| Cues | 1 | 2009 | 101 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 234 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 327 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 187 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3358 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3088 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 301 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 368 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 295 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 359 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 437 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2303 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5405 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 2665 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 623 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 34996 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 686 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 17371 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1598 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3140 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 6540 | 0.010 |
Why?
|